Description:
Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, particularly in relation to mode of action, dose intensity and chemotherapy regimes. This will lead on to a detailed study of the range of side effects commonly and uncommonly experienced by cancer patients undergoing chemotherapy treatment. Quality of life issues will also be discussed in terms of overall assessment and interpretation of results.
Detailed consideration will then be given to the treatment of lung, breast, upper GI, colorectal, ovarian, prostate and skin cancers. Each of these sessions, presented by clinicians active in these areas, will focus on overall patient presentation and management, diagnosis and staging. Our experts will then lead delegates in interactive group discussions of key issues relating to effective management of each of these tumor types.
The limitations of currently available cytotoxic drugs are well known. For this reason delegates will find the course includes in-depth discussions of new drug development and identification of new pharmacological targets of particular interest and value. Clinical trial design issues in early and randomised trials will also be covered.
Topics include:
Cancer: Terminology and classification
Introduction to anti-cancer drugs
Side effects of chemotherapy and radiotherapy
New developments in cancer therapy
Introduction to the major tumor types: breast, lung, colorectal, skin, ovarian, GI and prostate cancer
Clinical trials in oncology
Course Instructors:
Jeffrey Crawford MD
George Barth Geller Professor for Research in Cancer
Chief of Medical Oncology
Duke University Medical Center
North Carolina, USA
Nancy A Dawson MD
Professor of Medicine
Director, Genito-Urinary Medical Oncology
Georgetown University Hospital
Washington, USA
Adil Daud, MD
Associate Professor
Director, Melanoma Clinical Research
University of California, San Francisco
San Francisco, CA
Thierry M Jahan, MD
Assistant Professor of Medicine
Bonnie J & Anthony Addario Endowed Chair in Thoracic Oncology
Director, Clinical Services, Division of Hematology/Oncology
UCSF Helen Diller Comprehensive Cancer Center
San Francisco, USA
Maurie Markman, MD
Professor, Gynecologic Medical Oncology
Vice President, Clinical Research
MD Anderson Cancer Center
Texas, USA
Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trial Education
UCSF Helen Diller Comprehensive Cancer Center
San Francisco, USA
Alan Venook, MD
Professor of Clinical Medicine
Division of Medical Oncology
University of California, San Francisco
San Francisco, USA
Who Should Attend:
Healthcare’s courses are designed for both medical and non-medical staff within the pharmaceutical industry. This course is suitable for clinical research, medical information, regulatory affairs, biometrics and strategic marketing personnel.
Venue/Administrative Details:
The registration fee at our VIP Discount Rate is $3,752 USD (regular rate $4,169 USD). This includes lunch and refreshments throughout the day. Accommodation costs are not included. Delegates can register on-line or by completing the booking form and returning it together with the appropriate payment to Cambridge Healthtech Institute. Please retain a copy of the booking form for your records.
Schedule:
October 27:
8:30 am – 5:15 pm
October 28:
8:00 am – 5:30 pm